RSS
Healthcare: Pharmaceutical market: modest increase of 3.1% in 2012
The Romanian pharmaceutical market recorded last year 2.63 billion euro, on the rise by 3.1% compared to 2011, according to data of the analysis and study company Cegedim Romania, which estimates a possible drop in 2013.
“Market difficulties started to affect the most powerful companies and the prognosis remains modest for 2013, a rise of 1.4% in lei meaning a drop in euro or dollars. The most important problem is not at company level, although company problems have increased, but the quality and availability of medicine for patients, as well as that of medical service sin general. Claw-back market financing is not sustainable and the new authorities have a difficult mission in finding solutions both on a short term and medium term,” said Petru Craciun, general manager of Cegedim Romania.
In lei, last year’s increase was of 8.3%, below Cegedim prognosis of 8.9%, the market value reaching 11.71 billion lei.“The drop of the quarterly growth rate from 5.2% in quarter 3 to 3.9% in quarter four, combined with the annual increase rate of 8.3% for 2012, clearly show the temperate tendency of the pharmaceutical market, because of the evolution of constrictions, not of needs,” Craciun shows.
Compared to growth rates in the last five quarters, there has been a stagnation of units since 2012 (0.4%), a slight treatment increase (2.4%) and a decrease in lei (3.9%).
According to Cegedim, the market suffered as a result of measures to decrease public support and of extending payment terms, only some of the patients being able to maintain previous treatment levels. On distribution channels, growth rates in euro were of 2.6% for drug stores (2.27 billion euro) and 6.4% for hospitals (356 million euro).
The value of prescription medicines was 1.8% higher than in 2011, - 1.89 billion euro, while that of products without prescription the value went up by 6.6% to 375 million euro.
As for the top of the main ten corporations, it is led by Sanofi (including Zentiva and Sanofi-Pasteur) with sales of 978.3 million lei and a share of 8.4% followed by Hoffmann La Roche with 884.9 million lei and 7.6% market share and Novartis with 747.5 million lei and a market share of 6.4%.
The classification of the first ten players is completed by GlaxoSmithKline, Servier, Pfizer, AstraZeneca, Merck&Co, Ranbaxy and Abbott, with market shares between 5.4 and 3.4%.
On the echelon 11-20 we can find Antibiotice Iasi, KRKA, Johnson&Johnson, Teva, Bristol Myers Squibb, Manarini, Bayer, Eli Lilly and Gedeon Richter with market shares between 2.5 and 1.4%.